Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factorα

Ziqiang Yuan, Jessica Pastoriza, Thomas Quinn, Steven K. Libutti

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

An advantage of targeted gene therapy is the potential for effectively delivering anti-vascular and antitumor therapy directly to the site of the tumor, thus maximizing therapeutic efficacy and minimizing toxicity. The use of a vector capable of directed cell transduction can result in the sustained expression of the therapeutic agent. This chapter reviews the current status of vector strategies, targeted gene therapy with tumor-specific promoter and antibody and peptide conjugation, and outlines the challenges faced for the next-generation of gene transfer technology. Furthermore, it summarizes the results of preclinical anti-angiogenic gene therapy investigations, which utilize novel targeted tumor necrosis factorα treatment, and discusses potential clinical applications of this treatment strategy.

Original languageEnglish (US)
Title of host publicationGene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition
PublisherElsevier Inc.
Pages19-33
Number of pages15
ISBN (Print)9780123942951
DOIs
StatePublished - Aug 2013

Fingerprint

Dependovirus
Bacteriophages
Tumor Necrosis Factor-alpha
Genetic Therapy
Neoplasms
Neoplasm Antibodies
Technology Transfer
Therapeutics
Carcinogens
Blood Vessels
Peptides
Genes

Keywords

  • Adeno-associated virus phage
  • Antibody conjugation
  • Nonviral vector
  • Peptide conjugation
  • Targeted anti-angiogenic gene therapy
  • Tumor necrosis factorα
  • Tumor-specific promoter
  • Viral vector

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Cite this

Yuan, Z., Pastoriza, J., Quinn, T., & Libutti, S. K. (2013). Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factorα. In Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition (pp. 19-33). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-394295-1.00002-0

Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factorα. / Yuan, Ziqiang; Pastoriza, Jessica; Quinn, Thomas; Libutti, Steven K.

Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition. Elsevier Inc., 2013. p. 19-33.

Research output: Chapter in Book/Report/Conference proceedingChapter

Yuan, Z, Pastoriza, J, Quinn, T & Libutti, SK 2013, Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factorα. in Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition. Elsevier Inc., pp. 19-33. https://doi.org/10.1016/B978-0-12-394295-1.00002-0
Yuan Z, Pastoriza J, Quinn T, Libutti SK. Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factorα. In Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition. Elsevier Inc. 2013. p. 19-33 https://doi.org/10.1016/B978-0-12-394295-1.00002-0
Yuan, Ziqiang ; Pastoriza, Jessica ; Quinn, Thomas ; Libutti, Steven K. / Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factorα. Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition. Elsevier Inc., 2013. pp. 19-33
@inbook{31c43c4e862f47a09f08967c1372c5d9,
title = "Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factorα",
abstract = "An advantage of targeted gene therapy is the potential for effectively delivering anti-vascular and antitumor therapy directly to the site of the tumor, thus maximizing therapeutic efficacy and minimizing toxicity. The use of a vector capable of directed cell transduction can result in the sustained expression of the therapeutic agent. This chapter reviews the current status of vector strategies, targeted gene therapy with tumor-specific promoter and antibody and peptide conjugation, and outlines the challenges faced for the next-generation of gene transfer technology. Furthermore, it summarizes the results of preclinical anti-angiogenic gene therapy investigations, which utilize novel targeted tumor necrosis factorα treatment, and discusses potential clinical applications of this treatment strategy.",
keywords = "Adeno-associated virus phage, Antibody conjugation, Nonviral vector, Peptide conjugation, Targeted anti-angiogenic gene therapy, Tumor necrosis factorα, Tumor-specific promoter, Viral vector",
author = "Ziqiang Yuan and Jessica Pastoriza and Thomas Quinn and Libutti, {Steven K.}",
year = "2013",
month = "8",
doi = "10.1016/B978-0-12-394295-1.00002-0",
language = "English (US)",
isbn = "9780123942951",
pages = "19--33",
booktitle = "Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factorα

AU - Yuan, Ziqiang

AU - Pastoriza, Jessica

AU - Quinn, Thomas

AU - Libutti, Steven K.

PY - 2013/8

Y1 - 2013/8

N2 - An advantage of targeted gene therapy is the potential for effectively delivering anti-vascular and antitumor therapy directly to the site of the tumor, thus maximizing therapeutic efficacy and minimizing toxicity. The use of a vector capable of directed cell transduction can result in the sustained expression of the therapeutic agent. This chapter reviews the current status of vector strategies, targeted gene therapy with tumor-specific promoter and antibody and peptide conjugation, and outlines the challenges faced for the next-generation of gene transfer technology. Furthermore, it summarizes the results of preclinical anti-angiogenic gene therapy investigations, which utilize novel targeted tumor necrosis factorα treatment, and discusses potential clinical applications of this treatment strategy.

AB - An advantage of targeted gene therapy is the potential for effectively delivering anti-vascular and antitumor therapy directly to the site of the tumor, thus maximizing therapeutic efficacy and minimizing toxicity. The use of a vector capable of directed cell transduction can result in the sustained expression of the therapeutic agent. This chapter reviews the current status of vector strategies, targeted gene therapy with tumor-specific promoter and antibody and peptide conjugation, and outlines the challenges faced for the next-generation of gene transfer technology. Furthermore, it summarizes the results of preclinical anti-angiogenic gene therapy investigations, which utilize novel targeted tumor necrosis factorα treatment, and discusses potential clinical applications of this treatment strategy.

KW - Adeno-associated virus phage

KW - Antibody conjugation

KW - Nonviral vector

KW - Peptide conjugation

KW - Targeted anti-angiogenic gene therapy

KW - Tumor necrosis factorα

KW - Tumor-specific promoter

KW - Viral vector

UR - http://www.scopus.com/inward/record.url?scp=84904074751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904074751&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-394295-1.00002-0

DO - 10.1016/B978-0-12-394295-1.00002-0

M3 - Chapter

AN - SCOPUS:84904074751

SN - 9780123942951

SP - 19

EP - 33

BT - Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition

PB - Elsevier Inc.

ER -